First Time Loading...

Immunitybio Inc
NASDAQ:IBRX

Watchlist Manager
Immunitybio Inc Logo
Immunitybio Inc
NASDAQ:IBRX
Watchlist
Price: 9.15 USD 2.01%
Updated: May 6, 2024
Section:
 

Wall Street
Price Targets

IBRX Price Targets Summary
Immunitybio Inc

Wall Street analysts forecast IBRX stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IBRX is 7.65 USD with a low forecast of 6.06 USD and a high forecast of 9.45 USD.

IBRX Lowest Forecast
Wall Street Target
6.06 USD
34% Downside
IBRX Average Forecast
Wall Street Target
7.65 USD
16% Downside
IBRX Highest Forecast
Wall Street Target
9.45 USD
3% Upside
Lowest
Price Target
6.06 USD
34% Downside
Average
Price Target
7.65 USD
16% Downside
Highest
Price Target
9.45 USD
3% Upside
Immunitybio Inc Competitors:
Price Targets
AVCT
Avacta Group PLC
107% Upside
SPRO
Spero Therapeutics Inc
369% Upside
DYAI
Dyadic International Inc
435% Upside
CDMO
Avid Bioservices Inc
55% Upside
AVCT
Avacta Group PLC
107% Upside
SPRO
Spero Therapeutics Inc
369% Upside
DYAI
Dyadic International Inc
435% Upside
CDMO
Avid Bioservices Inc
55% Upside
VITR
Vitrolife AB
33% Upside
9966
Alphamab Oncology
62% Upside
ADMA
ADMA Biologics Inc
25% Upside
NKTX
Nkarta Inc
165% Upside

Revenue
Forecast

Revenue Estimate
Immunitybio Inc

For the last 8 years the compound annual growth rate for Immunitybio Inc's revenue is 13%. The projected CAGR for the next 3 years is 587%.

13%
Past Growth
587%
Estimated Growth
Estimates Accuracy
60%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Immunitybio Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Immunitybio Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-69%
Average Miss
What are analyst estimates?

See Also

Summary
IBRX intrinsic value, competitors valuation, and company profile.
DCF Valuation
IBRX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
IBRX stock valuation using valuation multiples.
Wall Street Estimates
IBRX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
IBRX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is IBRX's stock price target?
Price Target
7.65 USD

According to Wall Street analysts, the average 1-year price target for IBRX is 7.65 USD with a low forecast of 6.06 USD and a high forecast of 9.45 USD.

What is Immunitybio Inc's Revenue forecast?
Projected CAGR
587%

For the last 8 years the compound annual growth rate for Immunitybio Inc's revenue is 13%. The projected CAGR for the next 3 years is 587%.

ALPHA SPREAD
Join more than 134,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.